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Abstract
Background: The development of the innate and adaptive immune responses to Porcine reproductive and respiratory
syndrome virus (PRRSV) after vaccination of 1 day-old pigs with a PRRSV-1 based modified live virus (MLV) vaccine by
intramuscular (IM) and intranasal (IN) routes was characterised, before and after challenge with a heterologous PRRSV-1
isolate at 18 weeks post-vaccination. Twenty-five PRRSV-seronegative piglets were used. At 1 day of age, pigs were
administered with a single dose of vaccine via the IM (n = 10) or the IN route (n = 10). Control group (n = 5) received
saline solution. After vaccination, pigs were bled at days 3, 7, 28, 56, 83, 113 and 125. Levels of cytokines IL-10, IL-8, IFN-α
(measured by ELISA tests of serum), TNF-α and IFN-γ (measured by ELISA and ELISPOT, respectively, from stimulated
peripheral blood mononuclear cells), and serum neutralising antibodies (NA) to the vaccine strain, were measured.
Results: The induction of IL-10 was rare, indicating that IL-10 mediated immunomodulation/immune dysfunction was
not a feature of this vaccine or of the challenge virus. IL-8 was detected in only two pigs following vaccination, but in
the majority of pigs after challenge, indicating that their ability to produce an innate immune response was not
impaired. TNF-α was not detected in any vaccinated pigs until day 83. After challenge, only a minority of pigs
produced TNF-α. IFN-α was detected in all vaccinated pigs following vaccination, indicating the potential for
development of an effective Th1 adaptive immune response. IFN-γ-secreting cells were detected in all vaccinated
pigs after vaccination. NA to the vaccine strain were first detected at day 56 in pigs vaccinated by both routes, and
remained at similar levels until challenge. After challenge, a boost in NA was observed. The efficacy of the vaccine was
demonstrated by reduction of viraemia and nasal shedding after challenge.
Conclusions: The administration of a PRRSV-1 based MLV vaccine to 1 day-old piglets was able to induce an immune
response characterised by: (1) undetectable or low levels of IL-10, IL-8 and TNF-α, (2) an increase in IFN-α expression
within the first seven days, (3) a gradual increase in the number of antigen-specific IFN-γ-secreting cells, and (4)
induction of detectable NA. After challenge with a heterologous strain, there was a rapid boost in NA titres,
indicating a priming effect of the vaccine.
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Background
The development of an adaptive immune response to
Porcine reproductive and respiratory syndrome virus
(PRRSV) depends on both humoral and cellular compo-
nents [1]. The innate immune system is the first mechan-
ism of defence to prevent viral invasion and replication
and influences the adaptive response of the immune sys-
tem. Adequate early activation of the innate immune sys-
tem is critical to initiate generation of protective adaptive
immunity to achieve complete viral clearance [2]. How-
ever, PRRSV induces a slow and weak innate response [1].
The quantities of important cytokines secreted in pigs in-
fected by PRRSV, like IFN-α or IFN-γ, appeared to be sig-
nificantly lower than in pigs infected with Influenza A
virus or Porcine respiratory coronavirus [3–5]. The devel-
opment of neutralising antibodies (NA) is also known to
occur later in the course of the infection although
non-neutralising antibodies appear by 7–14 days post-in-
oculation [6]. In that way, both humoral and cell-mediated
specific immunity are delayed, compromising clearance of
the virus [7].
Serum NA also play an important role in the protec-
tion of animals against clinical disease. Passive transfer
of NA to pregnant sows (titres 1/16) can protect them
against reproductive failure by blocking transplacental
infection [8]. Using the same antibody transfer system, a
titre of 1/8 or higher protected piglets against the devel-
opment of viraemia, with sterilising immunity being ob-
tained at titres of 1/32 [9]. These results suggest that a
vaccine capable of inducing NA titres of 1/32 against a
given PRRSV strain should prevent the clinical disease
produced by it and could be an important tool in the
control of PRRSV [10]. It has to be taken into ac-
count, however, that these studies used a homologous
challenge model. Despite the significant role that NAs
seem to play in protection, their effectiveness might
be limited against heterologous isolates, as demon-
strated by the limited ability of PRRSV hyperimmune
sera to effectively neutralise a variety of heterologous
strains [11].
The nature of the protection induced by PRRSV MLV
vaccines against heterologous challenges is controversial.
Although it is widely accepted that heterologous protec-
tion is rather limited and strain dependent [12], con-
trasting models of the immune response have been
proposed for different PRRSV strains: one based on the
development of NA with low IFN-γ responses, the other
based on effective IFN-γ responses with a poor develop-
ment of NA [12].
Taken together, it is highly recommended to define the
profile of humoral and cell-mediated immunity induced
by a given MLV vaccine in order to predict its ability to
provide strong protection in front of challenge with
heterologous strains.
The ability of the immune system to fight against in-
fectious agents is conditioned by a sufficient degree of
functional maturation of the immune system [13]. It has
been demonstrated that the ability of monocytes and neutro-
phils from young pigs to produce pro-inflammatory cyto-
kines is reduced compared to those from adult pigs: the most
pronounced changes in cytokine production occurred at
weaning [13]. It should therefore be expected that the ability
of the immune system of a pre-weaning pig to respond to a
MLV vaccine could be reduced relative to older animals.
The objective of this study was to define the profile of
development of innate and adaptive immunity to PRRSV
after vaccination of 1-day-old pigs with a PRRSV-1
based MLV vaccine (Suvaxyn PRRS MLV), and after
challenge with a virulent heterologous field isolate of
PRRSV-1. One day old piglets were selected as they rep-
resent the “worse-case scenario” (youngest pigs) allowed
by the indications of the vaccine used. Two routes of
vaccine administration, intramuscular (IM) and intrana-
sal (IN), were evaluated. Challenge was delayed until 18
weeks after vaccination to ensure satisfactory duration
of immunity. Innate immunity was measured by evaluat-
ing the level of anti-inflammatory and pro-inflammatory
cytokines (IL-10, IL-8, TNF-α and IFN-α), humoral im-
munity by measuring the development of NA, and
cell-mediated immunity by evaluating the development
of IFN-γ- secreting cells.
Methods
Experimental design
Twenty-five piglets born from PRRSV-seronegative sows
were used, thus the potential impact of maternally de-
rived antibodies was not assessed in this study. The ani-
mals were allocated to treatments following a completely
randomised design. At 1 day of age, two groups of 10
pigs were administered a single 2 mL dose of vaccine via
the IM (T02) or the IN (T03) route. Five pigs from the
control group (T01) received 2 mL intramuscular and
2 mL intranasal of saline solution. After vaccination,
pigs were bled at days 3, 7, 28, 56, 83, 113 and 125.
Animals were housed by treatment with one pen per
treatment in the vaccination phase. Prior to challenge,
animals were re-housed and comingled in one room.
At 18 weeks post-vaccination (126 days), pigs were
challenged IN with the PRRSV-1 isolate Olot/91. Levels of
cytokines interleukin-10 (IL-10), interleukin-8 (IL-8),
interferon-alpha (IFN-α) and tumor necrosis factor-alpha
(TNF-α), number of interferon-gamma (IFN-γ) secreting
cells, and levels of NA to the vaccine strain, were mea-
sured at different time points after vaccination, and 6
days after challenge. Also, PRRSV viraemia and nasal
shedding were determined by RT-qPCR 1 day prior to
challenge and at days 3, 6, 8 and 10 after challenge.
Ten days post-challenge, pigs were euthanised.
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Throughout the experimental period the animals were
monitored daily for clinical observations.
Vaccination
Newborn piglets were used at 24 ± 12 h of age. The com-
mercial vaccine Suvaxyn PRRS MLV contains a deriva-
tive of the PRRSV-1 field isolate 96 V198, which has
been attenuated by serial passage on BHK21 cells engi-
neered to express the porcine CD163 PRRS receptor.
This vaccine was used, at minimum immunising dose
(2.2 log10 CCID50/dose), for T02 and T03 groups. At day
0, piglets in T02 were injected IM in the right side of
the neck. Piglets in T03 were administered IN, delivering
1.0 mL in each nostril. Piglets in T01 received saline so-
lution (2 mL IM and 2mL IN).
Challenge
At 18 weeks post-vaccination (126 days), pigs were chal-
lenged IN with the PRRSV-1 isolate Olot/91 [14], at a
dose of 105.8 CCID50/pig. The challenge virus is pas-
saged only on primary porcine alveolar macrophages in
order to ensure retention of virulence. The degree of
ORF7 and ORF5 nucleotide identity between the vaccine
virus and the challenge virus is 93.0 and 89.6%, respect-
ively. Although both viruses belong to subtype 1 of
PRRSV-1, they differ significantly in sequence.
Sampling
All pigs were bled before vaccination. After vaccination,
pigs were bled at days 3, 7, 28, 56, 83, 113 and 125. After
challenge (day 126), pigs were bled and nasal swabs were
taken at days 3, 6, 8 and 10 (study days 129, 132, 134
and 136).
Blood samples collected before vaccination (day 0) and
before challenge (day 125) were tested by PRRSV ELISA
(PRRS × 3, IDEXX) following manufacturer’s instructions.
Blood was collected in appropriate tubes to obtain
serum (PRRSV NA assay, PRRSV RT-qPCR and cytokine
ELISA tests for IL-10, IL-8 and IFN-α), and whole blood
in heparinised tubes (IFN-γ ELISPOT and TNF-α
ELISA). Nasal swabs were placed in 1 mL of PBS.
Cytokine analysis
Sera
Cytokines IL-8 and IL-10 in sera were measured by
ELISA using commercial pairs of monoclonal antibodies
(mAb) and according to the manufacturer’s instructions
(Porcine IL-8 and IL-10 ELISA Kits, Thermo Fisher
Scientific). The cut-off point of each ELISA was calcu-
lated as the mean + 3SD OD (optical density) of negative
controls. Cytokine concentrations were calculated by
using the linear regression formula from ODs of the
cytokine standards provided by the manufacturer. Re-
sults were expressed as pg/mL. IFN-α was measured as
previously reported [15] at days 3 and 7. Briefly, plates
were coated with anti-pig IFN-α (mAb K9, R&D sys-
tems) at 1.1 Ug/mL; 50 μl of each sample and biotinyl-
ated pig IFN-α (mAb F17, R&D systems) were added.
Positive reactions were revealed using Streptavidin-
Horseradish (Thermo Fisher Scientific) and soluble TMB
(Merck Millipore). IFN-α concentrations were calculated
according to the ODs obtained from the serial dilutions
of the recombinant porcine IFN-α protein (R&D sys-
tems), from 250 to 4 U/mL.
Peripheral blood mononuclear cell (PBMC) cultures
PBMC cultures were obtained from heparinised blood
samples by density-gradient centrifugation with Histopa-
que 1077 (Sigma). To measure TNF-α responses, PBMC
were seeded at a density of 1 × 106 cells per well in
96-well plates and were mock-stimulated or stimulated
with either PRRSV 96 V198 (vaccine strain) at a multi-
plicity of infection (moi) of 0.1, or 10 mg/ml of PHA.
After 24 h incubation, cell culture supernatants were col-
lected and frozen at − 80 °C until used. A TNF-α com-
mercial ELISA test (Porcine TNF-α ELISA Kit, Thermo
Fisher Scientific) was performed as above. To calculate
PRRSV-specific quantity of TNF-α, responses in un-
stimulated wells were subtracted from responses in
virus-stimulated wells. Results were expressed as pg/mL.
ELISPOT IFN-γ
PBMC were used to evaluate the frequencies of specific
IFN-γ-secreting cells (IFN-γ-SC) against the vaccine
strain by ELISPOT IFN-γ as reported elsewhere [16].
The ELISPOT assay was developed using commercial
mAbs (Porcine IFN-γ P2G10 and biotin P2C11, BD Bio-
sciences Pharmingen). PBMC were stimulated with the
PRRSV strain 96 V198 at a moi of 0.1; the stimulating
vaccine strain had been previously titrated in a
BHK-CD163 expressing cell line by end-point limiting
dilution and it was adjusted to the corresponding moi
just prior to conducting the test. Unstimulated and
PHA-stimulated cells (10 μg/mL) were used as negative
and positive controls, respectively. All tests were done in
quadruplicate. Reactions were developed by adding
3-amino-9-ethylcarbazole as substrate. PRRSV-specific
frequencies of IFN-γ-SC were calculated by subtracting
counts of spots in unstimulated wells from counts in
PRRSV-stimulated wells and were expressed as number
of responding cells in 5 × 106 PBMC.
PRRSV serum neutralisation assay
Inactivated serum samples were serially diluted two-fold
(1:2 to 1:4096) in 96-well plates. PRRSV strain 96 V198
vaccine virus suspension (125 μl) containing 800
CCID50/mL was added to each well and plates were in-
cubated for 1 h at 36–38 °C. A BHK21-CD163 expressing
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cell suspension [17] containing 2.5-3 × 105 cells/mL was
prepared and 100 μL aliquoted to each well in a new plate.
Fifty microliters of each serum-virus mix were transferred
to the plate containing cells. The mixture was incubated
at 36–38 °C and 5% CO2 for five days. A direct immuno-
fluorescence assay technique using FITC-conjugated
monoclonal antibody SDOW-17 (Rural Technologies Inc)
was performed. The NA titre was determined as the
inverse of the last dilution of serum that inhibited the
FA signal.
PRRSV RT-qPCR
RNA was purified from serum and nasal swab samples
using the Biosprint 96 DNA Blood kit. Viraemia was
measured by means of a Reverse Transcription (RT)
qPCR. In brief, the purified viral RNA was used as tem-
plate, reverse transcribed at 50 °C for 30 min, and dena-
tured at 95 °C for 5 min. The PCR program of reactions
consisted of 40 cycles of denaturation at 95 °C for 20 s
and annealing at 53 °C for 40 s. The qRT-PCR was con-
ducted in a 7500 Real-Time PCR System thermal cycler.
The oligonucleotide primers and dual-labeled probe
used for amplification were 5’-GCACCACCTCACCC
AGAC- 3′ (forward, final concentration 0.5 μM); 5’-
CAGTTCCTGCGCCTTGAT- 3′ (reverse, final concen-
tration 0.5 μM); and 5′-6-FAM-CCTCTGCTTGCAAT
CGATCCAGAC- BHQ1–3′ (dual-labeled probe, final
concentration 0.6 μM), which correspond to base pair
positions 14,792–14,809, 14,851–14,868, and 14,819–
14,842, respectively, of the EU prototype strain Lelystad
(Genbank accession number M96262). The amplicon
consists of a 77-bp fragment from ORF7.
The genome equivalents (RNA copy number per 5 μL)
were interpolated from the RNA standard curve for this
assay and adjusted (RNA copy number per 1 mL of sam-
ple) according to the sample dilution.
Data analysis
Data summaries and analyses were performed with a
centralised data management system (SAS/STAT User’s
Guide Version 9.3 or higher, SAS Institute, Cary, NC).
Only post-challenge data (once animals were comingled)
were analysed. Pre-challenge data was summarised with
descriptive statistics, since the experimental unit (the
pen) was not replicated. Post-challenge data was ana-
lysed, since animals had been commingled and the ex-
perimental unit was the individual animal. Prior to
statistical analysis, results were transformed, where ne-
cessary, using an appropriate logarithm transformation.
For tests that had a single result after being moved
into challenge housing, the transformed data were ana-
lysed using a general linear mixed model with fixed ef-
fects: treatment. For tests that had multiple results after
being moved into challenge housing, the transformed
data were analysed using a general linear repeated mea-
sures mixed model with fixed effects: treatment, time
point, and treatment by time point interaction; and ran-
dom effects: animal within treatment, which is the ani-
mal term.
Prior to statistical analysis the RT-qPCR was trans-
formed using an appropriate logarithm transformation.
The transformed data was analysed using a general lin-
ear repeated measured mixed model. Pairwise treatment
comparisons were made at each time point if the treat-
ment or treatment by time point interaction effect was
significant (P ≤ 0.05). Treatment least squares mean and
95% confidence intervals were back-transformed for pres-
entation. Negative samples were given a value of 50 PRRSV
RNA copies/mL (1.7 log10 PRRSV RNA copies/mL), which
corresponds to a half of the quantification limit of the tech-
nique (100 PRRSV RNA copies/mL).
Viraemia and nasal shedding were analysed with a
general linear repeated measures mixed model with a
logit link with fixed effects: treatment, time point, and
treatment by time point interaction, and random effects:
pen, block within pen, and animal within block, pen,
and treatment, which is the animal term.
Linear combinations of the parameter estimates were
used in a priori contrasts after testing for a significant
(P ≤ 0.05) treatment effect or treatment by time point
interaction. Comparisons were made between treatments
at each time point. The 5% level of significance (P ≤
0.05) was used to assess statistical differences. Least
squares means (back transformed), standard errors, and
95% confidence intervals of the means were calculated
for each treatment and time point. If the model did not
converge, Fisher’s Exact were used for the analysis.
Results
Clinical observations
Eight weeks after vaccination an infectious urinary
process, characterised by cystitis, urinary bladder rup-
ture and peritonitis, occurred in the pigs allocated into
the vaccinated groups (T02 and T03). One pig from T02
and two pigs from T03 died. All pigs were treated with
enrofloxacin (7.5 mg/kg IM). Another pig, belonging to
T02, died during the bleeding process at D56. The rest
of the pigs remained healthy during the post-vaccination
period. After challenge, no clinical signs associated with
PRRSV infection were observed in pigs of any of the
treatment groups.
Viraemia and nasal shedding
All pigs were non-viraemic before vaccination and be-
fore challenge. After challenge, all control animals (T01)
became viraemic at Day 129 (3 days after challenge), co-
inciding with the peak of viraemia. The length of vir-
aemia was at least 10 days, since all control pigs were
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still viraemic at the end of the study. In pigs vaccinated
by the IM route (T02), viraemia was detected in 8/10
pigs, and in 2 pigs it was not detected throughout the
post-challenge period. The peak of viraemia was also at
3 days after challenge, although the virus load was more
than 2.0 log lower than in control pigs (Table 1). At the
end of the study, 10 days after challenge, all IM vacci-
nated pigs but one had already cleared the virus from
blood. In pigs vaccinated by IN route (T03), viraemia
was detected in at least one time point in all animals in
the post-challenge period. The peak of viraemia was also
at 3 days after challenge, although the virus load was
more than 1.0 log lower than in control pigs (Table 1).
At the end of the study, 10 days after challenge, all IN
vaccinated pigs but two had already cleared the virus
from blood.
Viral loads (Table 1) were significantly lower in IM
vaccinated than in control pigs at days 3, 6, 8 and 10
after challenge; also, viral loads were significantly lower
in IN vaccinated than in control pigs at days 6, 8 and 10
after challenge. The percentage of pigs viraemic was sig-
nificantly lower at days 8 (p = 0.0047) and 10 (p = 0.0210)
after challenge in both IM and IN vaccinated groups,
compared to non-vaccinated pigs.
The viral load detected in nasal swabs (Table 2) was
significantly lower in IM vaccinated than in control pigs
at days 3 and 6 after challenge; viral loads were not sig-
nificantly lower in IN vaccinated than in control pigs
after challenge (Table 2). The percentage of shedding
pigs was significantly lower in the IM vaccinated group,
compared to the control group, at 3 days after challenge.
No significant differences were detected between the IN
vaccinated group and control group, or between the vac-
cinated groups.
Cell mediated immunity
Il-10
IL-10 was measured after vaccination (Days 3 and 7),
and 6 days after challenge, Day 132 (Table 3, Fig. 1).
Control pigs (T01) did not produce measurable IL-10
during the vaccination phase. After challenge, IL-10 was
detected in one out of 5 control pigs. In pigs vaccinated
by the IM route (T02), IL-10 was not produced after
vaccination. After challenge, IL-10 was detected in one
out of 8 pigs. In pigs vaccinated by the IN route (T03),
IL-10 was produced in 1 out of 10 pigs after vaccination
at Day 3. However, IL-10 was not detected in any pig at
Day 7. After challenge, IL-10 was detected in 2 out of 6
tested pigs. Differences on IL-10 levels at Day 132 were
not statistically significant between vaccinated and con-
trol groups, nor between vaccinated groups.
Il-8
IL-8 was measured after vaccination (Days 3 and 7), and
6 days after challenge, Day 132 (Table 3, Fig. 2). Control
pigs (T01) did not produce measurable IL-8 during the
vaccination phase. After challenge, IL-8 was detected in 3
out of 5 control pigs. In pigs vaccinated by the IM route
(T02), IL-8 was not produced after vaccination at Day 3.
However, IL-8 was produced in 1 out of 10 pigs at Day 7.
After challenge, IL-8 was detected in 3 out of 8 pigs. In
pigs vaccinated by the IN route (T03), IL-8 was not pro-
duced after vaccination at Day 3. However, IL-8 was pro-
duced in 1 out of 10 pigs at Day 7. After challenge, IL-8
was detected in 6 out of 8 pigs. Differences on IL-8 levels
at Day 132 were not statistically significant between vacci-
nated and control groups, nor between vaccinated groups.
IFN-α
IFN-α was measured after vaccination at Days 3 and 7
(Table 3, Fig. 3). Control pigs (T01) did not produce meas-
urable IFN-α during the vaccination phase, except in one
out of 5 pigs, in which low amounts of IFN-α were de-
tected at Day 3. At Day 7, IFN-α was not detected in any
control pig. In pigs vaccinated by the IM route (T02),
IFN-α was produced in all pigs at Day 3 and at Day 7. In
pigs vaccinated by the IN route (T03), IFN-α was pro-
duced in 9 out of 10 pigs at Day 3, and in all pigs at Day 7.
Table 1 Mean (±SD) viral load in serum after challenge and percentage of viraemic pigs
Treatment Day of study
125/DC-1 129/DC + 3 132/DC + 6 134/DC + 8 136/DC + 10
Viral
load
% viraemic
pigs
Viral load % viraemic
pigs
Viral load % viraemic
pigs
Viral load % viraemic
pigs
Viral load % viraemic
pigs
Mean PRRSV
viral load
T01 ND 0% 6.01 ± 0.3 100% 4.72 ± 0.1 100% 4.21 ± 0.3 100% 5.32 ± 0.8 100%
T02 ND 0% 3.57 ± 0.6 62.5% 2.90 ± 0.5 50% 1.80 ± 0.1 12.5% 2.11 ± 0.5 12.5%
T03 ND 0% 4.74 ± 0.7 87.5% 3.80 ± 0.4 87.5% 2.15 ± 0.3 25% 1.86 ± 0.1 25%
Contrast
P value T01 vs T02 0.0059 NS 0.0054 NS 0.0016 0.0047 0.0087 0.0047
T01 vs T03 NS NS 0.0458 NS 0.0011 0.0210 0.0096 0.0210
T02 vs T03 NS NS NS NS NS NS NS NS
Values are expressed as log10 PRRSV RNA copies per mL of serum. DC day of challenge, ND non-detectable (below limit of detection of the technique), NS non-significant
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Table 2 Mean (±SD) viral load in nasal swabs after challenge and percentage of shedder pigs
Treatment Day of study
125/DC-1 129/DC + 3 132/DC + 6 134/DC + 8 136/DC + 10
Viral load % shedder
pigs
Viral load % shedder
pigs
Viral load % shedder
pigs
Viral load % shedder
pigs
Viral load % shedder
pigs
Mean PRRSV
viral load
T01 ND 0% 5.56 ± 0.7 100% 4.53 ± 0.5 100% 2.07 ± 0.3 20% 2.10 ± 0.4 20%
T02 ND 0% 2.21 ± 0.6 12.5% 2.64 ± 0.4 37.5% ND 0% 2.03 ± 0.3 25%
T03 ND 0% 3.72 ± 0.6 62.5% 3.19 ± 0.4 62.5% 2.06 ± 0.2 25% 2.52 ± 0.3 37.5%
Contrast
P value T01 vs T02 0.0019 0.0047 0.0119 NS NS NS NS NS
T01 vs T03 NS NS NS NS NS NS NS NS
T02 vs T03 NS NS NS NS NS NS NS NS
Values are expressed as log10 PRRSV RNA copies per mL. DC day of challenge, ND non-detectable (below limit of detection of the technique), NS non-significant
Table 3 Cytokine measure geometric mean (±SD) results
Treatment Day of study
3 7 28 83 125 (DC-1) 132 (DC + 6)
IL-10 T01 ND ND 4.8 ± 1.0 (1/5)
T02 ND ND 5.2 ± 1.7 (1/8)
T03 ND ND 10.1 ± 6.4 (2/8)
P value T01 vs T02 NS
T01 vs T03 NS
T02 vs T03 NS
IL-8 T01 ND ND 48.1 ± 22.9 (3/5)
T02 ND ND 33.8 ± 12.7 (3/8)
T03 ND ND 69.6 ± 26.2 (6/8)
P value T01 vs T02 NS
T01 vs T03 NS
T02 vs T03 NS
IFN-α T01 ND 1.9 ± 0.0 (1/5)
T02 9.8 ± 6.1 (10/10) 32.8 ± 11.8 (10/10)
T03 9.5 ± 9.7 (9/10) 14.1 ± 9.9 (10/10)
TNF-α T01 ND ND (1/5)a ND 62.7 ± 7.6 (1/5) ND 29.1 ± 1.5
T02 ND ND ND ND (1/8)a ND 41.9 ± 1.6 (1/8)
T03 ND ND ND ND (2/8)a ND 78.2 ± 2.9 (1/8)
P value T01 vs T02 NS
T01 vs T03 NS
T02 vs T03 NS
IFN-γ T01 1.6 ± 0.0 (5/5) 1.6 ± 0.0 (4/5) 0.0 ± 0.0 (3/4) 8.1 ± 0.5 (3/4)
T02 22.1 ± 1.1 (9/10) 80.5 ± 8.2 (8/8) 166.5 ± 7.1 (8/8) 133.5 ± 5.7 (8/8)
T03 51.3 ± 4.1 (8/9) 77.2 ± 8.2 (8/8) 102.2 ± 4.3 (8/8) 155.7 ± 6.6 (8/8)
P value T01 vs T02 0.0003 0.0033
T01 vs T03 0.0108 0.0011
T02 vs T03 NS NS
aAlthough some pigs had values above the cut-off of the technique, the mean value was below the cut-off
Results from IL-10, IL-8, IFN-α and TNF-α ELISA tests are expressed as pg/mL of serum. Results from IFN-γ ELISPOT are expressed as number of IFN-γ- secreting
cells /5 × 105 PBMC. In brackets, the number of positive animals per treatment and time point. DC day of challenge, ND non-detectable (below limit of detection
of the technique), NS non-significant; blank cell indicates not measured
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TNF-α
TNF-α was measured during the vaccination phase
(Days 3, 7, 28, 83 and 125), and 6 days after chal-
lenge, Day 132 (Table 3, Fig. 4). Control pigs (T01)
did not produce measurable TNF-α during the vaccin-
ation phase, except in one out of 5 pigs, in which
low amounts of TNF-α were detected at Day 7, and
another pig at Day 83. Just before challenge and after
challenge, it was not detected in any pig. In pigs vac-
cinated by the IM route (T02), TNF-α was not pro-
duced after vaccination, except for 1 animal that
produced very low amounts of TNF-α at Day 83.
After challenge, TNF-α was detected in one out of 8
pigs. In pigs vaccinated by the IN route (T03), TNF-α
was not produced after vaccination, except for 2 ani-
mals at Day 83. After challenge, TNF-α was detected
in one out of 8 pigs. Differences on TNF-α levels at
Days 125 and 132 were not statistically significant be-
tween vaccinated and control groups, nor between
vaccinated groups.
IFN-γ
IFN-γ-SC were measured during the vaccination phase
(Days 28, 83 and 125), and 6 days after challenge, Day
Fig. 1 Evolution of IL-10 levels (red line indicates limit of detection: 7.8 pg/mL)
Fig. 2 Evolution of IL-8 levels (red line indicates limit of detection: 31.25 pg/mL)
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132 (Table 3, Fig. 5). Control pigs (T01) produced
very low IFN-γ secreting cells during the post-vaccination
period. After challenge, there was a mild increase in
the number of IFN-γ-SC. In pigs vaccinated by the
IM route (T02), the number of IFN-γ-SC increased
from 22 to 166 during the post-vaccination period,
and were 133 after challenge. In pigs vaccinated by
the IN route (T03), the number of IFN-γ-SC in-
creased from 51 to 102 during the post-vaccination
period, and to 155 after challenge. Differences in the
number of IFN-γ-SC at Days 125 and 132 were statis-
tically significant between vaccinated (both IM and
IN) and control groups, but not between the vacci-
nated groups.
Humoral immunity
All pigs were seronegative to PRRSV antibodies detected
by ELISA before vaccination. Before challenge, at day
125, control pigs (T01) remained seronegative (mean S/P
ratio 0.011), while vaccinated pigs (T02 and T03) had ser-
oconverted. The geometric mean antibody titres were
1.681 for T02 and 1.103 for T03.
NA were measured during the vaccination phase (Days
28, 56, 83, 113 and 125), and 6 days after challenge, Day
132 (Table 4, Fig. 6). Control pigs (T01) had low to un-
detectable NA titres throughout the study. All vacci-
nated pigs developed some level of NA after vaccination
and before challenge. In pigs vaccinated by the IM route
(T02), NA were first detected at Day 56 after vaccination
Fig. 3 Evolution of IFN-α levels (Limit of detection: 3.9 pg/mL)
Fig. 4 Evolution of TNF- α levels (red line indicates limit of detection: 62.5 pg/mL)
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(geometric mean of 4.9), and were kept at very similar
levels until challenge. After challenge, NA titres went
from 4.6 (Day 125, day before challenge) to 14.7 (Day
132, 6 days after challenge). In pigs vaccinated by the IN
route (T03), NA were first detected at Day 56 after vac-
cination (geometric mean of 4.5), and were kept at very
similar levels until challenge. After challenge, NA titres
went from 2.3 (Day 125, day before challenge) to 16.1
(Day 132, 6 days after challenge). Differences in NA ti-
tres at Day 132 were statistically significant between vac-
cinated and control groups. Differences in NA titres at
Day 125 were statistically significant between pigs vacci-
nated by the IM route and control pigs, but not between
the IN vaccinated group and the control group.
Discussion
PRRSV is known to interact with the immune system of
the host and to modulate the immune response after in-
fection. PRRSV induces a slow and weak innate immune
response [3, 4], and a delayed adaptive immune response
[1, 6, 15]. The objective of this study was to characterise
the development of the innate, humoral and cell medi-
ated immune responses to PRRSV after vaccination of
1-day-old naïve pigs with a PRRSV-1 based MLV vaccine
by the IM and IN routes, before and after challenge with
a PRRSV-1 isolate at 18 weeks post-vaccination. Levels
of cytokines IL-10, IL-8, IFN-α, TNF-α and IFN-γ, as
well as levels of NA, were measured.
IL-10 is an anti-inflammatory cytokine which has been
linked to regulatory T cell activity and to decreased cell-
mediated immune responses, by inhibiting the induction
of pro-inflammatory cytokines such as IFN-γ and TNF-α
[18]. It has been hypothesised that in some strains of
PRRSV the induction of IL-10 pushes the immune re-
sponse towards a relatively ineffective induction of IFN-γ
specific response [19]. In this study, the induction of de-
tectable levels of IL-10 was rare, both after vaccination
and after challenge. During the post-vaccination phase, a
Fig. 5 Evolution of the number of IFN-γ secreting cells, expressed as number of IFN-γ producing cells /5 × 105 PBMC
Table 4 Serum NA test geometric mean (±SD) results
Treatment Day of study
28 56 83 113 125 (DC-1) 132 (DC + 6)
SN antibody inverse titre T01 ND ND ND ND ND ND
T02 ND 4.9 ± 3.5 3.1 ± 3.3 3.9 ± 4.0 4.6 ± 1.4 14.7 ± 4.4
T03 ND 4.5 ± 3.9 2.3 ± 3.0 2.7 ± 2.7 2.3 ± 0.7 16.1 ± 4.8
Contrast
P value T01 vs T02 0.0149 <.0001
T01 vs T03 NS <.0001
T02 vs T03 NS NS
Titres are expressed as the inverse of the highest dilution at which NA activity is detected. DC day of challenge, ND non-detectable (below limit of detection of
the technique), NS non-significant
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single pig (from the IN-vaccinated group) showed induc-
tion of a low level of IL-10 (10.9 pg/mL). After challenge
with the Olot/91 strain, four pigs were positive for IL-10
with levels up to 346.6 pg/mL. The near absence of meas-
urable IL-10 induction by the vaccine virus indicates that
vaccination did not induce any significant response attrib-
utable to this regulatory cytokine, either in the period of
innate response (day 3) or in later stages of the trial. IL-10
mediated immunomodulation/ immune dysfunction was
not a general feature of this vaccine strain, as demon-
strated by induction of a high number of IFN-γ-SC. This
is a positive feature of the vaccine strain, since IL-10 has
been related to an inhibition of the development of an ef-
fective immune response against PRRSV [10].
IL-8 is a pro-inflammatory cytokine that induces
chemotaxis in target cells, primarily neutrophils and
other granulocytes, causing them to migrate towards the
site of infection [20]. Usually macrophages detect anti-
gen first, and are the first cells to release IL-8 to recruit
other cells. Some studies have linked an IL-8 response to
enhanced resistance to PRRSV infection [21, 22]. In this
study IL-8 was detected in only two pigs following vac-
cination, and not at all in the non-vaccinated group, sug-
gesting that the vaccine did not generate intense
inflammatory reactions. Young pigs have a reduced abil-
ity to produce IL-8 in response to an immune stimula-
tion, compared to adults [13]. However, IL-8 was
detected in the majority of vaccinated and non-vacci-
nated pigs after challenge, indicating that the ability of
pigs to produce IL-8 was not impaired after challenge.
There were no significant differences between the vacci-
nated and non-vaccinated groups. The lack of induction
of this pro-inflammatory cytokine is consistent with the
good safety profile of the vaccine (no systemic or local
reactions observed after vaccination; data not shown).
TNF-α is involved in systemic inflammation and acute
phase reaction as a pro-inflammatory cytokine. It is pro-
duced mainly by activated macrophages, although it can be
produced by other cell types. Being an endogenous pyro-
gen, TNF-α is able to induce fever, apoptotic cell death,
cachexia, inflammation, and to enhance viral replication
[23]. In the present study, TNF-α was not detected in any
vaccinated pigs before challenge. After challenge, only a mi-
nority of pigs in all three groups produced detectible levels
of TNF-α, confirming the inhibitory effect of PRRSV on the
induction of pro-inflammatory cytokines.
IFN-α is a type I interferon produced by infected cells,
and mediates the first line of defense against viral infec-
tion (innate antiviral cytokine). Interaction of IFN-α with
receptors on target cells establishes a potent antiviral
state. In addition, IFN-α serves as an important link be-
tween innate and adaptive immunity, and can enhance
the development of a strong T helper type 1 (Th1) in-
flammatory response [1]. IFN-α induction has been re-
ported to be weak or absent for some PRRSV strains.
The active inhibition of IFN-α production, and inhib-
ition of various IFN-induced cellular gene products, has
been attributed to specific viral proteins and implicated
as a primary cause of the impaired immune responses to
the virus [1, 24]. In this study, IFN-α was detected in all
vaccinated pigs, regardless of route. IFN-α levels in-
creased between days 3 and 7 following vaccination,
while remaining low in the non-vaccinated control
group. These results would be consistent with the devel-
opment of antiviral responses. Consistent induction of
IFN-α secretion shortly after vaccination indicates the
Fig. 6 Evolution of SN titers (inverse titer). Positive ≥2
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potential for development of an effective Th1 adaptive
immune response dominated by IFN-γ, which was dem-
onstrated by frequencies of IFN-γ-SC in response to the
virus well above 100 per million.
IFN-γ (type II interferon) is a pro-immune cytokine
that has an ability to inhibit viral replication directly, but
its most important function is immunomodulatory.
IFN-γ is the primary cytokine that defines Th1 cells:
Th1 cells secrete IFN-γ, as do natural killer (NK) cells. It
is considered to be correlated with protection, although
IFN-γ response in PRRSV infected pigs appears to be
delayed [7, 25], and it is considered to be weak, com-
pared to other swine viruses such as Aujeszky’s Disease
virus [1]. In the current study, IFN-γ-SC were detected
in all vaccinated pigs, increased steadily in number be-
tween days 28 and 125 post-vaccination, and remained
high after challenge (means of 133 and 156 cells/5 × 105
PBMC in the IM and IN treatments, respectively), con-
firming that vaccination can positively modulate IFN-γ
gene expression and sustain IFN-γ secretion when cells
are re-stimulated [7]. The number of IFN-γ-SC in
non-vaccinated pigs remained low.
As mentioned, IL-8 and TNF-α are pro-inflammatory
cytokines induced in some PRRSV infections. In this
study IL-8 and TNF-α were either not detected, or de-
tected in only in a minority of animals after vaccination.
However, both innate and adaptive immune responses
could be clearly demonstrated following vaccination by
the production of IFN-α and subsequent development of
IFN-γ-SC. Induction of IL-8 or TNF-α by the vaccine
could have been harmful to 1-day-old pigs. The near
absence of these pro-inflammatory cytokines may
contribute to the observed safety of this vaccine in
pre-weaning pigs.
All pigs became effectively vaccinated, as indicated by
the seroconversion (by ELISA) of all pigs from both vac-
cinated groups. Levels of NA after vaccination were in
the expected range for a PRRSV MLV vaccine. Neutralis-
ing antibodies to the vaccine strain were first detected at
Day 56 in pigs vaccinated by either the IN or IM route,
and were sustained at similar levels until challenge. After
challenge, a boost in NA was observed in both vacci-
nated groups, while no evidence of a response was ob-
served in the non-vaccinated group. Interestingly, no
differences were seen for IN and IM vaccinated pigs. At
challenge (Day 126) NA levels were significantly higher
in IM-vaccinated pigs than in the non-vaccinated control
group, and at Day 132 both IM and IN-vaccinated
groups were significantly higher than the control group.
In piglets, titres above 1/8 have been correlated with
protection against homologous reinfection [6]. In the
present study NA titres prior to challenge did not reach
this value. However, it is generally acknowledged that
protection against PRRSV infection is not mediated be
neutralizing antibodies alone, and includes an important
cell-mediated component [1]. In this study, an almost
complete clearance of viraemia was achieved 10 days
after challenge, in 80% of the animals vaccinated by
the IM route. All these animals had detectable levels
of NA and IFN-γ-SC, consistent with humoral and
cell-mediated immunity both contributing to the con-
trol of infection.
Viraemia and nasal shedding results confirmed that
vaccine protected pigs using both administration routes.
All animals belonging to the control group were still vir-
aemic at 10 days after challenge; in contrast, only 1/8 IM
vaccinated pigs and 2/8 IN vaccinated pigs were vir-
aemic at day 10, indicating that the immunity induced
by the vaccine was able to clear the challenge virus from
blood. Specifically, it was noted that those animals hav-
ing a high NA titre at challenge were able to clear vir-
aemia in 6–8 days, or even did not become viraemic.
One IM-vaccinated animal with a low NA titre at chal-
lenge did not become viraemic, but had the highest
IFN-γ response. NA and IFN-γ responses were mea-
sured against the vaccine strain only. Results would
likely be different (lower) against a heterologous virus,
such as the challenge virus used in this study. However,
it is important to establish homologous baseline perform-
ance of the vaccine before considering the effects on
heterologous cross-reaction on these immunoassays. The
ability of the vaccine to protect against this heterologous
challenge virus is evident from the viraemia results. The
magnitude of the induction of NA and IFN-γ-SC (using
homologous antigen) will serve as an important internal
control in future studies with other challenge viruses.
Differences (other than minor) in the development of
the immune response or in the efficacy of the vaccine
were not observed between pigs vaccinated by the IM or
IN routes. Since the mechanism of development of pro-
tection is not known for this vaccine, it was of interest
to try both routes of administration. It could be specu-
lated that both routes result in vaccine virus replication
and development of a systemic immune response under
these conditions.
It has been demonstrated that 1 day-old pigs can have
a reduced ability to respond to immunological stimula-
tion compared to pigs of weaning age [13]. The present
study has demonstrated that piglets vaccinated at 1 day
of age can develop innate, humoral and cell-mediated
immune responses that are sufficient to protected them
from a wild type PRRSV challenge up to at least 16
weeks after vaccination. One explanation for this appar-
ent contradiction is the live nature of this vaccine. The
vaccine virus actively replicates for weeks following vac-
cination, without causing disease, allowing time for the
immune system of the neonatal pig to reach a greater
level of maturity before eliminating the vaccine virus.
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In conclusion, the administration of a PRRSV-1 based
MLV to 1-day-old naïve piglets, derived from PRRS-free
parent stock, was able to induce innate, cell mediated
and humoral immune responses characterised by: (1)
undetectable or low levels of IL-10, IL-8 and TNF-α in
vaccinated pigs, (2) a mean 7-fold (IN) or 13-fold (IM)
increase in IFN-α expression within the first 7 days, ob-
served in all vaccinated pigs, (3) a gradual increase in
the number of antigen-specific IFN-γ-SC, from near zero
to ≥100 cells/5 × 105 PBMC between days 28 post-vac-
cination and challenge, observed in all vaccinated pigs,
and (4) induction of detectable NA in all vaccinated pigs
by Day 56. After challenge with a heterologous field
strain, there was a rapid boost in NA titres that was not
observed in the non-vaccinated control group, indicating
a priming effect of the vaccine.
Conclusions
The administration of a PRRSV-1 based MLV to
1-day-old naïve piglets is able to induce innate, cell me-
diated and humoral immune responses characterised by:
 Undetectable levels of IL-10, IL-8 and TNF-α
 Seven- (IN) to 13-fold (IM) increase in IFN-α
expression
 Gradual increase of IFN-γ-SC
 NA induction
After challenge with a heterologous wild type strain, a
cellular immune response mediated by IFN-γ and a
humoral immune response which elicited NA were able
to prevent or reduce the replication of the challenge
virus and allow a faster clearance of viraemia.
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